Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)
Procedure'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
NCT Number: NCT02585154
Parkinson's disease is a common, disabling, progressive condition characterised by severe problems with movement for which medical treatment in the longer term can be unsatisfactory. Deep brain stimulation is a treatment, which directly stimulates the nerve cells affected inside the brain to help overcome the difficulties with movement. Classically, deep brain stimulation stimulates in a manner that is constant and independent of a patients underlying condition as reflected in their brainwave activity. Recent research has suggested that adjusting deep brain stimulation in real time using analyses of brain signals recorded from deep brain stimulation electrodes (termed closed loop deep brain stimulation) nay be better than classical deep brain stimulation in alleviating difficulties with movement. However, it remains unclear whether closed-loop deep brain stimulation also leads to fewer unwanted side effects on movement control. In order to answer this question, the investigators will analyze deep brain stimulation activity and activity recorded from the surface of the head in Parkinson's disease patients undergoing deep brain stimulation surgery. During the recordings patients will perform different movement tasks. Deep brain stimulation has been found to reduce patients' ability to suppress inappropriate movements in certain tasks and performance in these tasks will be the core point of interest. The recordings will be conducted three times: During closed loop deep brain stimulation, classical deep brain stimulation and while the stimulator is turned off. This will allow the investigators to assess putative differences in the effect of closed loop and classical deep brain stimulation with regards to wanted and unwanted effects on movement control and to elucidate their correlates in the brain.
Looking for future studies?
Notify Me18 year–74 year
All sexes
Interventional
Not applicable
University College London Hospitals NHS Trust, London, United Kingdom
Study Summary Patients will undergo standard 2 part deep brain stimulation implantation (electrode implantation day 1, battery and stimulator implantation approximately day 7, home approximately day 10). The experiments will be performed whilst the patients are inpatients between the two operations and will therefore not require any extra visits or delay in starting therapeutic deep brain stimulation. This paradigm is the standard method for conducting local field potential research in human and represents the paradigm by which the vast majority of previous research in this area has been conducted. Patients will be tested either at Oxford University Hospitals National Health Service Trust or University College London National Health Service Trust.
At least 24h after electrode implantation (first of the two surgeries) patients will be approached about the study and left with the patient information sheet for 24 hours, before further discussion, and, if appropriate consent.
Thereafter, the following procedures will be undertaken:
Prior to the next steps, which will be conducted on the same day or 1-3 days later(depending on the preferences of the participant), participants will be requested to withhold their usual medication overnight so that they are assessed off medication on the morning of the tests.
Prior to recordings we will assess motor impairment using a validated clinical score and patients will have the opportunity to familiarize themselves with the motor tasks.
Completion of the recordings will mark the end of an individual's participation in the study. Given the overall duration of the study patients will be offered the opportunity to complete the recordings after overnight withdrawal of dopaminergic medication over two days or on one single day if preferred.
Thereafter the patient will have their stimulator implanted as usual (most often 7 days after the first operation) and they will be discharged on day 9 - 10 according to their clinical recovery.
For patients with already implanted pacemakers, suitable participants will be identified by the Functional Neurosurgery team who follow the clinical care of the patients. The invitation letter and information sheet will be provided by the clinical team on behalf of the researchers. If patients are interested, they would then be asked to contact the researchers. The same assessments as above (rating scales, motor tasks) will be conducted on one single day in the National Hospital for Neurology and Neurosurgery, London.
Clinical intervention:
Externalisation of electrode wires. The externalisation of the electrode wires will be performed by trained neurosurgeons. This will occur in the awake patient under local anaesthetic (or under a brief general anaesthetic if independent assessment of the patient's clinical state by an anaesthetist determines this to be necessary) in the neurosurgical department.
Research intervention:
Single blinded counterbalanced within-subject trial. Patients will undergo closed loop deep brain stimulation, open loop deep brain stimulation and a session without deep brain stimulation whilst performing motor tasks. Local field potential and electroencephalographic activity will be simultaneously recorded.
Closed loop deep brain stimulation will be delivered through a portable battery operated electronic device connected to the externalised leads. This incorporates an amplifier that allows brain waves to be recorded during deep brain stimulation, a controller and a stimulator. The controller is a simple rectifier and level detector, which then operates a switch that allows stimulation. The level detector is adjusted so that deep brain stimulation is only allowed when a certain clinician determined threshold of pathological brain wave activity is exceeded. The stimulator supplies stimulation at a frequency of 130 Hertz and a voltage as used for standard clinical stimulation. The device weighs about 350 grams and is most simply carried in a small shoulder bag, or attached to a belt.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
Deep Brain Stimulation, which is applied depending on ongoing brain activity.
Deep Brain Stimulation is turned off.
Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
Time frame: Outcome will be assessed on day of experimental sessions (interventions), i.e. the time frame corresponds to the study duration.
Time frame: Outcome will be assessed on day of experimental sessions (interventions), i.e. the time frame corresponds to the study duration.
Time frame: Outcome will be assessed on day of experimental sessions (interventions), i.e. the time frame corresponds to the study duration.
Estimate frequencies from 2 to 35 Hz.
Time frame: Outcome will be assessed on day of experimental sessions (interventions), i.e. the time frame corresponds to the study duration.
Estimate frequencies from 2 to 35 Hz.
University of Oxford
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06133283
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial DetailsNCT05766813
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07723027
Basal Ganglia Diseases, Brain Diseases
Shakargarh, Punjab Province, Pakistan
View Trial DetailsNCT07361250
Basal Ganglia Diseases, Brain Diseases
Wuhan, Hubei, China
View Trial Details